Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

AIMS: Two phase 1, open‐label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL) plus imipenem/cilastatin (IMI). METHODS: Study PN005 evaluated the PK of REL (125 mg) plus IM...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Bhagunde, Pratik, Colon‐Gonzalez, Francheska, Liu, Yang, Wu, Jin, Xu, Shiyao Sherrie, Garrett, Graigory, Jumes, Patricia, Lasseter, Kenneth, Marbury, Thomas, Rizk, Matthew L., Lala, Mallika, Rhee, Elizabeth G., Butterton, Joan R., Boundy, Keith
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163372/
https://ncbi.nlm.nih.gov/pubmed/31856304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados